Should drug makers be banned from buying back stock? Take our reader poll
A new analysis finds many drug makers spent more on buying back stock and paying dividends than on research and development.
Drug makers often argue that innovation would suffer whenever they are attacked for high prices. But a new analysis finds many of these companies have actually spent more on buying
